Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health

Generated: May 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,960,424

« Back to Dashboard

Summary for Patent: 7,960,424
Title:Liquid pharmaceutical formulations of palonosetron
Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
Inventor(s): Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Varese, IT), Cannella; Roberta (Varese, IT), Braglia; Enrico (Pazzallo, CH), Braglia; Riccardo (Pazzallo, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M. (Palo Alto, CA)
Assignee: Helsinn Healthcare S.A. (Lugano, CH) Roche Palo Alto LLC (Palo Alto, CA)
Application Number:11/388,270
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,960,424
Patent Claims: 1. A pharmaceutically stable isotonic intravenous solution of palonosetron hydrochloride for reducing emesis or reducing the likelihood of emesis comprising a) from about 0.03 mg/mL to about 0.2 mg/mL palonosetron as palonosetron hydrochloride, b) a sterile pharmaceutically acceptable aqueous carrier comprising mannitol as a tonicity agent, at a pH of from 4.0 to 6.0, and c) EDTA in an amount of from 0.005 to 1.0 mg/mL.

2. The solution of claim 1 wherein the palonosetron is in a concentration of about 0.05 mg/mL as palonosetron hydrochloride.

3. The solution of claim 1 wherein the pH is from 4.5 to 5.5.

4. The solution of claim 1 wherein the pharmaceutically acceptable carrier further comprises citric acid.

5. The solution of claim 1 wherein: a) said palonosetron is present in a concentration of 0.05 mg/ml, as palonosetron hydrochloride; and b) said EDTA is present in a concentration of from 0.005 to 1.0 mg/ml.

6. The solution of claim 5 wherein said pH is from 4.5 to 5.5.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Boehringer Ingelheim
Argus Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.